Clinical Trial Update: A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works [Phase 3]

View source ↗

Summary

Phase 3 study evaluating long-term safety and efficacy of Pozelimab plus Cemdisiran in adults with paroxysmal nocturnal hemoglobinuria; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• Cemdisiran (cemdisiran)
• Pozelimab

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Status: RECRUITING